» Articles » PMID: 26497532

Fc Receptors in Antibody-dependent Enhancement of Viral Infections

Overview
Journal Immunol Rev
Date 2015 Oct 27
PMID 26497532
Citations 151
Authors
Affiliations
Soon will be listed here.
Abstract

Sensitization of the humoral immune response to invading viruses and production of antiviral antibodies forms part of the host antiviral repertoire. Paradoxically, for a number of viral pathogens, under certain conditions, antibodies provide an attractive means of enhanced virus entry and replication in a number of cell types. Known as antibody-dependent enhancement (ADE) of infection, the phenomenon occurs when virus-antibody immunocomplexes interact with cells bearing complement or Fc receptors, promoting internalization of the virus and increasing infection. Frequently associated with exacerbation of viral disease, ADE of infection presents a major obstacle to the prevention of viral disease by vaccination and is thought to be partly responsible for the adverse effects of novel antiviral therapeutics such as intravenous immunoglobulins. There is a growing body of work examining the intracellular signaling pathways and epitopes responsible for mediating ADE, with a view to aiding rational design of antiviral strategies. With in vitro studies also confirming ADE as a feature of infection for a growing number of viruses, challenges remain in understanding the multilayered molecular mechanisms of ADE and its effect on viral pathogenesis.

Citing Articles

Antibody-dependent enhancement of ORFV uptake into host cells.

Tang X, Zhang C, Geng Q, Chen D, Ma W Virulence. 2025; 16(1):2466503.

PMID: 39954287 PMC: 11834454. DOI: 10.1080/21505594.2025.2466503.


Adjuvant Use of the Invariant-Natural-Killer-T-Cell Agonist α-Galactosylceramide Leads to Vaccine-Associated Enhanced Respiratory Disease in Influenza-Vaccinated Pigs.

Artiaga B, Madden D, Kwon T, McDowell C, Keating C, Balaraman V Vaccines (Basel). 2024; 12(9.

PMID: 39340098 PMC: 11435877. DOI: 10.3390/vaccines12091068.


Analysis of Beyfortus (Nirsevimab) Immunization Campaign: Effectiveness, Biases, and ADE Risks in RSV Prevention.

Banoun H Curr Issues Mol Biol. 2024; 46(9):10369-10395.

PMID: 39329969 PMC: 11431526. DOI: 10.3390/cimb46090617.


A deterministic model for homologous antibody dependant enhancement on influenza infection.

Xu S, Yang J Infect Dis Model. 2024; 9(4):1265-1275.

PMID: 39183947 PMC: 11342263. DOI: 10.1016/j.idm.2024.07.003.


Vaccine Platform Comparison: Protective Efficacy against Lethal Marburg Virus Challenge in the Hamster Model.

ODonnell K, Henderson C, Anhalt H, Fusco J, Erasmus J, Lambe T Int J Mol Sci. 2024; 25(15).

PMID: 39126087 PMC: 11313278. DOI: 10.3390/ijms25158516.


References
1.
van de Veerdonk F, Netea M . New Insights in the Immunobiology of IL-1 Family Members. Front Immunol. 2013; 4:167. PMC: 3703542. DOI: 10.3389/fimmu.2013.00167. View

2.
Halstead S, Shotwell H, Casals J . Studies on the pathogenesis of dengue infection in monkeys. II. Clinical laboratory responses to heterologous infection. J Infect Dis. 1973; 128(1):15-22. DOI: 10.1093/infdis/128.1.15. View

3.
Srivastava R, Ramakrishna C, Cantin E . Anti-inflammatory activity of intravenous immunoglobulins protects against West Nile virus encephalitis. J Gen Virol. 2015; 96(Pt 6):1347-1357. PMC: 4635485. DOI: 10.1099/vir.0.000079. View

4.
Gao R, Cao B, Hu Y, Feng Z, Wang D, Hu W . Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med. 2013; 368(20):1888-97. DOI: 10.1056/NEJMoa1304459. View

5.
Suhrbier A, Jaffar-Bandjee M, Gasque P . Arthritogenic alphaviruses--an overview. Nat Rev Rheumatol. 2012; 8(7):420-9. DOI: 10.1038/nrrheum.2012.64. View